Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant PharmovaBOM:530019 +0.27%70 Return-on-Tangible-Equity is 15.97% as of Mar. 2026, which is 53% below its 10-year median of 33.92. GuruFocus rates BOM:530019 with a GF Score™ of 70/100 and a GF Value™ of ₹1,069.84 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, Jubilant Pharmova ranks better than 68.37% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Jubilant Pharmova's annualized net income for the quarter that ended in Mar. 2026 was ₹4,776 Mil. Jubilant Pharmova's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹29,901 Mil. Therefore, Jubilant Pharmova's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 15.97%.
The historical rank and industry rank for Jubilant Pharmova's Return-on-Tangible-Equity or its related term are showing as below:
BOM:530019'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2.93 Med: 33.92 Max: 78.19
Current: 14.24
During the past 13 years, Jubilant Pharmova's highest Return-on-Tangible-Equity was 78.19%. The lowest was -2.93%. And the median was 33.92%.
BOM:530019's Return-on-Tangible-Equity is ranked better than 68.37% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs BOM:530019: 14.24
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jubilant Pharmova Return-on-Tangible-Equity Related Terms
Jubilant Pharmova Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530019 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.97% mean?
Jubilant Pharmova (BOM:530019) has a Return-on-Tangible-Equity of 15.97% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jubilant Pharmova and its competitors. This is 53% below median its historical median of 33.92. According to the industry distribution chart, Jubilant Pharmova ranks #285 out of 901 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Jubilant Pharmova's Return-on-Tangible-Equity too high?
Jubilant Pharmova's current Return-on-Tangible-Equity of 15.97% is 53% below median its 10-year median of 33.92. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Jubilant Pharmova's value of 15.97% is 102.9% above this industry median. Based on the distribution chart, Jubilant Pharmova ranks #285 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #285 out of 901 companies for Return-on-Tangible-Equity. This puts Jubilant Pharmova in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.87. Jubilant Pharmova's value of 15.97% is 102.9% above this benchmark. While the company's 10-year median is 33.92 vs. the industry median of 7.87, Jubilant Pharmova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Return-on-Tangible-Equity of 15.97% is 102.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Return-on-Tangible-Equity is 15.97%, which is 53% below median its own 10-year median of 33.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,069.84, compared to a current price of ₹933.35 — trading 12.8% below its estimated fair value. The current Return-on-Tangible-Equity is 15.97%, which is 53% below median its 10-year median of 33.92 and 102.9% above the Drug Manufacturers industry median of 7.87. Jubilant Pharmova's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Return-on-Tangible-Equity is 15.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹933.35 is trading 12.8% below its estimated GF Value™ of ₹1,069.84.
GuruFocus considers Jubilant Pharmova to be Modestly Undervalued.
Key valuation signals for BOM:530019:
Return-on-Tangible-Equity: 15.97% (53% below median its 10-year median of 33.92)
GF Value™: ₹1,069.84 vs. price of ₹933.35 (12.8% below fair value)
Industry Position: 102.9% above the Drug Manufacturers median (#285 of 901)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
70GF Score
Get the complete analysis for BOM:530019
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
